SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 5, 2002
REPLIGEN CORPORATION
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 000-14656 04-2729386
(State or Other Jurisdiction of Commission (I.R.S. Employer
Incorporation) File Number) Identification No.)
117 Fourth Avenue,
Needham, Massachusetts 02494
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (781) 449-9560
No change since last report
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On April 5, 2002, Repligen Corporation announced that the United States
Food and Drug Administration (FDA) has granted approval to market SecreFlo(TM)
(synthetic porcine secretin), the first synthetic version of the hormone
secretin. SecreFlo(TM) has been approved for stimulation of pancreatic
secretions.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Financial Statements of Business Acquired: None required.
(b) Pro Forma Financial Information: None required.
(c) Exhibits:
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated April 5, 2002.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
REPLIGEN CORPORATION
By: /s/ Walter C. Herlihy
-------------------------
Name: Walter C. Herlihy
Title: President and Chief Executive Officer
Date: April 9, 2002
-2-
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated April 5, 2002.
-3-